De-Escalation Dual Antiplatelet Strategy in Stabilized Myocardial Infarction Patients With Diabetes Mellitus
JACC: Cardiovascular Interventions · 2025-11 · 18 (22) · 2713-2724
DOI: 10.1016/j.jcin.2025.09.026 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift JACC: Cardiovascular Interventions, 2025-11. Verfasst von Sang Hyun Kim und 13 weiteren Autor:innen. Beteiligte Einrichtung: Division of Cardiology, Department of Internal Medicine, Seoul St. Mary's Hospital, The Catholic University of Korea, Seoul, Republic of Korea; Divis…. Hauptthemen laut MEDLINE: Ticagrelor, Platelet Aggregation Inhibitors, Percutaneous Coronary Intervention, Clopidogrel. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 41 Literaturangaben.
Themen: Diabetes mellitus
Abstract (Originalsprache)
BACKGROUND: Diabetes mellitus (DM) is associated with suboptimal clopidogrel response and elevated thrombotic risk. The benefit of early de-escalation of dual antiplatelet therapy (DAPT) in DM patients with myocardial infarction (MI) undergoing percutaneous coronary intervention (PCI) remains uncertain. OBJECTIVES: The authors sought to assess whether a 1-month, unguided de-escalation from ticagrelor to clopidogrel is associated with clinical benefit compared with continued ticagrelor-based DAPT in MI patients with DM. METHODS: This post hoc analysis included 859 patients with DM (31.9%) from the TALOS-AMI (Ticagrelor Versus Clopidogrel in Stabilized Patients With Acute Myocardial Infarction) trial who tolerated 1 month of ticagrelor-based DAPT post-PCI. Participants were randomized to continue ticagrelor or switch to clopidogrel for 11 months. The primary endpoint was a composite of ischemic (cardiovascular death, MI, and stroke), and bleeding (Bleeding Academic Research Consortium [BARC] type 2, 3, or 5 bleeding) endpoints. RESULTS: De-escalation was consistently associated with a lower incidence of primary endpoint compared with continued ticagrelor (mainly driven by fewer BARC type 2 bleeding events), irrespective of diabetes status (Pinteraction = 0.467). In the DM cohort, differences in bleeding (HR: 0.48; 95% CI: 0.22-1.05; P = 0.066) and ischemic (HR: 0.57; 95% CI: 0.25-1.29; P = 0.176) endpoints were not significant. Results were consistent across subgroups stratified by glycemic control and PCI complexity. Significant treatment-by-DM interactions were observed for BARC type 3 or 5 bleeding (Pinteraction = 0.042) and target vessel revascularization (Pinteraction = 0.014). CONCLUSIONS: In MI patients with DM, 1-month unguided de-escalation to clopidogrel after ticagrelor-based DAPT was associated with clinical benefit without increasing ischemic risk. These results warrant further prospective validation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Cardiology, Department of Internal Medicine, Seoul St. Mary's Hospital, The Catholic University of Korea, Seoul, Republic of Korea; Division of Cardiology, Department of Internal Medicine, The Armed Forces C…
- Division of Cardiology, Department of Internal Medicine, Seoul St. Mary's Hospital, The Catholic University of Korea, Seoul, Republic of Korea; Catholic Research Institute for Intractable Cardiovascular Disease, College…
- Division of Cardiology, Department of Internal Medicine, Incheon St. Mary's Hospital, The Catholic University of Korea, Incheon, Republic of Korea.
- Division of Cardiology, Department of Internal Medicine, Uijeongbu St. Mary's Hospital, The Catholic University of Korea, Uijeongbu, Republic of Korea.
- Division of Cardiology, Department of Internal Medicine, Seoul St. Mary's Hospital, The Catholic University of Korea, Seoul, Republic of Korea.
- School of Public Health, San Diego State University, San Diego, California, USA; Herbert Wertheim School of Public Health & Human Longevity Science, University of California, La Jolla, California, USA.
Zitieren
APA
Kim, S. H., Lee, K. Y., Byeon, J., Jang, J., Hwang, B. H., Choo, E. H., Lim, S., Lee, M., Kim, C. J., Choi, I. J., Park, M. W., Kim, D. B., Chang, K., & TALOS-AMI Investigators (2025). De-Escalation Dual Antiplatelet Strategy in Stabilized Myocardial Infarction Patients With Diabetes Mellitus. JACC: Cardiovascular Interventions, 18(22), 2713-2724. https://doi.org/10.1016/j.jcin.2025.09.026
Vancouver
Kim SH, Lee KY, Byeon J, Jang J, Hwang BH, Choo EH, et al. De-Escalation Dual Antiplatelet Strategy in Stabilized Myocardial Infarction Patients With Diabetes Mellitus. JACC: Cardiovascular Interventions. 2025;18(22):2713-2724. doi:10.1016/j.jcin.2025.09.026
BibTeX
@article{Kim2025,
author = {Kim, Sang Hyun and Lee, Kwan Yong and Byeon, Jaeho and Jang, Jaehyuk and Hwang, Byung-Hee and Choo, Eun-Ho and Lim, Sungmin and Lee, Myunhee and Kim, Chan Joon and Choi, Ik Jun and Park, Mahn-Won and Kim, Dong-Bin and Chang, Kiyuk and TALOS-AMI Investigators, TALOS-AMI Investigators},
title = {De-Escalation Dual Antiplatelet Strategy in Stabilized Myocardial Infarction Patients With Diabetes Mellitus},
journal = {JACC: Cardiovascular Interventions},
year = {2025},
volume = {18},
number = {22},
pages = {2713--2724},
doi = {10.1016/j.jcin.2025.09.026}
}
EUVIMED